| Title |
Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2016
|
| DOI | 10.1007/s00280-016-3190-8 |
| Pubmed ID | |
| Authors |
Labidi Soumaya, Mejri Nesrine, El Benna Houda, Afrit Mehdi, Lakhdhar Sarra, Boussen Hamouda |
| Abstract |
We aim to evaluate prevalence and characteristics of CTS in routine daily practice over a 5-year period, with a review of the literature. Patients treated with endocrine therapy (441) were retrospectively analyzed looking for CTS cases in aromatase inhibitors (219, 49.6%) and in tamoxifen (222, 50.3%) patients. We described patient's characteristics and CTS management. We also reviewed the literature reporting CTS in aromatase inhibitors clinical trials. Six cases of CTS were diagnosed, all in patients on aromatase inhibitors given in the adjuvant setting. Prevalence was 2.7%. Median age was 54 years. CTS occurred under anastrozole in four cases and letrozole in two cases. One patient had severe intensity presentation. Median time to symptoms onset was 14 months, and resolution was obtained within 4 months after a nonsurgical treatment. Aromatase inhibitor-induced CTS is rare. It should be recognized and treated in order to avoid endocrine therapy discontinuation. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 21% |
| Other | 2 | 8% |
| Researcher | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Other | 4 | 17% |
| Unknown | 7 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 17% |
| Nursing and Health Professions | 2 | 8% |
| Agricultural and Biological Sciences | 1 | 4% |
| Chemistry | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 8 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2016.
All research outputs
#21,164,509
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,211
of 2,501 outputs
Outputs of similar age
#271,948
of 313,916 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#21
of 26 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,916 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.